HLFHERBALIFE LTD.
Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Revenue
- $5.0B
- 0.9% YoY
- Operating margin
- 9.5%
- 24% YoY
- EBITDA
- $602M
- 19% YoY
- Market cap
- $1.4B
- Employees
- 8,500
- $593K revenue each
- Net debt / EBITDA
- 2.2×
- $1.3B net debt
- AI in 10-K
- 1.6
- mentions per 10K words
Takeover score 1 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo146% of net incomeCash flow under 80% of net income
- Dilutive SBCNo1% of revenueOver 10% of revenue
- Payouts exceed cash flowNo2% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo4% of assetsOver 40% of assets
- Shareholder dissentNo91% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo$593K · 25th pctBottom quartile of its SIC industry
- Quiet on AINo1.6 per 10K words · 48th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo2.2× EBITDA net debtMore cash than debt, positive EBITDA
- Buyout-sizedYes$1.4B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$2M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $5.8B | $5.2B | $5.1B | $5.0B | $5.0B | 0.9% |
| Operating income | $734M | $545M | $356M | $386M | $481M | 25% |
| Net income | $447M | $321M | $142M | $254M | $228M | 10% |
| Operating cash flow | $460M | $353M | $358M | $285M | $333M | 17% |
| Capex | $151M | $156M | $135M | $122M | $80M | 34% |
| Stock-based comp | $54M | $44M | $48M | $50M | $44M | 12% |
| Buybacks | $1.0B | $147M | $11M | $8M | $8M | 1.2% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| May 6, 2021 | ICAHN CARL C | SC 13D/A | 0.0% | Passive |
| Jan 4, 2021 | ICAHN CARL C | SC 13D/A | 3.9% | Passive |
| Nov 5, 2020 | ICAHN CARL C | SC 13D/A | — | Passive |
| Aug 17, 2020 | ICAHN CARL C | SC 13D/A | 15.5% | Active |
| Aug 12, 2020 | ICAHN CARL C | SC 13D/A | — | Active |
| Oct 30, 2019 | ICAHN CARL C | SC 13D/A | 19.1% | Passive |
Insider trading
- Open-market buys, 12 mo
- $182K · 4
- Open-market sells, 12 mo
- $3M · 4
- Net
- −$2M
Pay vs performance
No pay-versus-performance disclosure yet.